Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus (NASDAQ: EOLS) has announced the approval of inducement grants for 34 newly hired non-executive employees. The compensation package includes 26,897 non-qualified stock options and 99,826 restricted stock units (RSUs). The stock options, priced at $13.11 per share, have a 10-year term and vest over 4 years, with 25% vesting annually. Similarly, the RSUs vest 25% each year over four years, starting February 7, 2025.
These grants were approved under Evolus' 2023 Inducement Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The awards are contingent upon continuous employment through each vesting date.
Evolus (NASDAQ: EOLS) ha annunciato l'approvazione di concessioni di incentivazione per 34 nuovi dipendenti non esecutivi. Il pacchetto di compenso comprende 26.897 opzioni su azioni non qualificate e 99.826 unità di azioni riservate (RSU). Le opzioni su azioni, valutate a $13,11 per azione, hanno un termine di 10 anni e si maturano in 4 anni, con il 25% che matura annualmente. Allo stesso modo, le RSU maturano il 25% ogni anno per quattro anni, a partire dal 7 febbraio 2025.
Queste concessioni sono state approvate nell'ambito del Piano di Incentivazione per Induzione 2023 di Evolus e sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4). I premi dipendono da un continuo impiego fino alla data di maturazione di ciascuna concessione.
Evolus (NASDAQ: EOLS) ha anunciado la aprobación de concesiones de incentivo para 34 nuevos empleados no ejecutivos. El paquete de compensación incluye 26,897 opciones de acciones no cualificadas y 99,826 unidades de acciones restringidas (RSUs). Las opciones de acciones, con un precio de $13.11 por acción, tienen un plazo de 10 años y se consolidan en un período de 4 años, con el 25% consolidándose anualmente. De manera similar, las RSUs se consolidan un 25% cada año durante cuatro años, comenzando a partir del 7 de febrero de 2025.
Estas concesiones fueron aprobadas bajo el Plan de Incentivos por Inducción 2023 de Evolus y cumplen con la Regla de Cotización de Nasdaq 5635(c)(4). Los premios están sujetos a empleo continuo hasta cada fecha de consolidación.
이볼루스 (NASDAQ: EOLS)는 34명의 신규 비임원 직원에게 유인 보상 승인을 발표했습니다. 보상 패키지는 26,897개의 비면세 주식 옵션과 99,826개의 제한 주식 단위(RSU)를 포함합니다. 주식 옵션은 주당 $13.11로 가격이 책정되며, 10년의 유효 기간을 가지고 4년 동안 매년 25%씩 분할 지급됩니다. 비슷하게, RSU도 4년에 걸쳐 매년 25%씩 지급되며, 2025년 2월 7일부터 시작됩니다.
이러한 보상은 이볼루스의 2023 유인 보상 계획에 따라 승인되었으며 나스닥 상장 규칙 5635(c)(4)를 준수합니다. 이러한 보상은 각각의 분할 지급일에 계속 고용되어 있어야 합니다.
Evolus (NASDAQ: EOLS) a annoncé l'approbation de concessions d'incitation pour 34 nouveaux employés non exécutifs. Le paquet de rémunération comprend 26 897 options d'actions non qualifiées et 99 826 unités d'actions restreintes (RSU). Les options d'actions, évaluées à 13,11 $ par action, ont une durée de 10 ans et acquièrent des droits sur une période de 4 ans, avec 25 % des droits acquis chaque année. De même, les RSU acquièrent 25 % chaque année pendant quatre ans, à partir du 7 février 2025.
Ces concessions ont été approuvées dans le cadre du Plan d'incitation à l'induction 2023 d'Evolus et sont conformes à la règle d'inscription Nasdaq 5635(c)(4). Les récompenses sont conditionnées par un emploi continu jusqu'à chaque date d'acquisition.
Evolus (NASDAQ: EOLS) hat die Genehmigung von Anreizzuweisungen für 34 neu eingestellte nicht-executive Mitarbeiter bekannt gegeben. Das Vergütungspaket umfasst 26.897 nicht qualifizierte Aktienoptionen und 99.826 eingeschränkte Aktieneinheiten (RSUs). Die Aktienoptionen, die zu einem Preis von $13,11 pro Aktie angeboten werden, haben eine Laufzeit von 10 Jahren und werden über 4 Jahre mit 25% jährlicher Vesting fällig. Ähnlich werden die RSUs ebenfalls über vier Jahre verteilt, wobei jährlich 25% fällig werden, beginnend ab dem 7. Februar 2025.
Diese Zuweisungen wurden im Rahmen des Anreizplans für 2023 von Evolus genehmigt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Die Auszeichnungen stehen unter dem Vorbehalt einer durchgehenden Beschäftigung bis zu jedem Vesting-Datum.
- Expansion of workforce with 34 new non-executive hires indicates company growth
- Structured equity compensation plan helps align employee interests with shareholders
- Potential dilution of existing shareholders through new stock options and RSUs issuance
The stock options have an exercise price of
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive
Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Estyme® is a trademark of Symatese Aesthetics S.A.S.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250207494454/en/
Evolus Contacts:
Investors:
Nareg Sagherian
Vice President, Head of Global Investor Relations and Corporate Communications
Tel: 248-202-9267
Email: ir@evolus.com
Media:
Email: media@evolus.com
Source: Evolus
FAQ
How many shares are included in Evolus (EOLS) February 2025 inducement grants?
What is the exercise price for EOLS stock options granted in February 2025?
What is the vesting schedule for Evolus (EOLS) February 2025 inducement grants?
How many new employees received EOLS inducement grants in February 2025?
